Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Bacampicillin→

Bacampicillin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
50972-17-3
Molecular formula
C21H27N3O7S
Molecular weight
465.5 g/mol
Drug class
Oral ester prodrug of ampicillinaminopenicillin beta-lactam antibacterial
Mechanism of action
Bacampicillin is hydrolysed by esterases to ampicillin after absorption. Ampicillin binds penicillin-binding proteins and inhibits bacterial peptidoglycan cell-wall synthesis, producing bactericidal activity against susceptible organisms.
Indications / reported uses
  • Treatment of infections caused by ampicillin-susceptible bacteria in countries where bacampicillin products remain authorised; exact indications and availability are jurisdiction-specific and should follow current local antimicrobial guidance

Sources: PubMed — Bacampicillin pharmacology and conversion to ampicillin · NLM MeSH — Bacampicillin · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Bacampicillin Environmental Risk Assessment (ERA) (the Bacampicillin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.